Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 50,386 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

A Study Comparing the Efficacy and Safety of Orally Administered Ibuprofen and Placebo in Delayed Onset Muscle Soreness

NCT02113566
View directory record Official record
Conditions
Delayed Onset Muscle Soreness
Interventions
Acetaminophen 1000mg
Drug
Lead sponsor
Jean Brown Research
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 23, 2026, 2:24 AM EDT
Recruiting Phase 4 Interventional

Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty

NCT06384651
View directory record Official record
Conditions
Infections, Ankle Arthritis
Interventions
Intraosseous Vancomycin Injection, Intravenous Vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)

NCT04449029
View directory record Official record
Conditions
Hepatitis B
Interventions
GSK3228836, Placebo, Nucleos(t)ide therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

NCT02621931
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
179
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

A Study of Inhaled AZD8630 in Adolescents With Asthma

NCT07065331
View directory record Official record
Conditions
Asthma
Interventions
AZD8630, Dry powder inhaler
Drug · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
9
States / cities
Bakersfield, California • Miami Lakes, Florida • Lafayette, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

NCT04269031
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD2373 subcutaneous injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

Treatment of Parkinson's Disease With a Transdermal Skin Patch

NCT00001931
View directory record Official record
Conditions
Parkinson Disease
Interventions
N-0923
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 1Phase 2 Interventional

Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum

NCT00086931
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD

NCT02176031
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Natalizumab, Methylprednisolone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART

NCT01403051
View directory record Official record
Conditions
HIV-1 Infection
Interventions
EFV/FTC/TDF, Calcium Carbonate, Vitamin D3, Placebo for calcium carbonate, Placebo for vitamin D3
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Not applicable Interventional

IVF Clinical Trial of Two Different Treatment Protocols.

NCT00799929
View directory record Official record
Conditions
Infertility
Interventions
in vitro fertilization (IVF/ICSI)
Other
Lead sponsor
New Hope Fertility Center
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Not applicable Interventional

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

NCT02113631
View directory record Official record
Conditions
Hepatitis C, Chronic, Cirrhosis
Interventions
Telaprevir, Boceprevir, Peg-IFN, Ribavirin
Drug
Lead sponsor
Louis Stokes VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

Pediatric Schizophrenia Efficacy and Safety Study

NCT01911429
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone 40 mg, Lurasidone 80 mg, Placebo 40 or 80 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
36
States / cities
Dothan, Alabama • Anaheim, California • Bakersfield, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 23, 2026, 2:24 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT02521870
View directory record Official record
Conditions
Metastatic Melanoma, Head Neck Cancer
Interventions
SD-101(1), Pembrolizumab, SD-101(2), SD-101(3)
Drug · Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
30
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 23, 2026, 2:24 AM EDT
Completed No phase listed Observational

5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor

NCT02632370
View directory record Official record
Conditions
Malignant Gliomas
Interventions
Gliolan®, Fluorescence-Guided Surgery
Drug · Procedure
Lead sponsor
Constantinos Hadjipanayis
Other
Eligibility
18 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
17
States / cities
Washington D.C., District of Columbia • Delray Beach, Florida • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 23, 2026, 2:24 AM EDT
Recruiting Phase 2 Interventional

Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism

NCT04798469
View directory record Official record
Conditions
Opioid Use, Pain, Hypogonadism, Male
Interventions
Testosterone Undecanoate 250 MG/ML, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

NCT03959241
View directory record Official record
Conditions
Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
Interventions
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, Cyclophosphamide
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 23, 2026, 2:24 AM EDT
Recruiting Phase 4 Interventional

Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections

NCT06982105
View directory record Official record
Conditions
Methicillin Resistant Staphylococcus Aureus, Osteomyelitis Acute, Septic Arthritis, Orbital Cellulitis, Facial Cellulitis, Mastoiditis, Cervical Adenitis, Retropharyngeal Abscess, Peritonsillar Abscess
Interventions
Trimethoprim Sulfamethoxazole
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 23, 2026, 2:24 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

NCT02835794
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Omacetaxine, Azacitidine, G-CSF
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults

NCT02350751
View directory record Official record
Conditions
Influenza
Interventions
MEDI8852, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 23, 2026, 2:24 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Use of Exercise Snacks to Improve Upper Body Fitness

NCT07362329
View directory record Official record
Conditions
Muscle Strength, Muscle Power, Physical Endurance
Interventions
Submaximal Repeated Exercise Snack, Maximal One-Time Exercise Snack
Behavioral
Lead sponsor
New York Institute of Technology
Other
Eligibility
20 Years to 35 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

NCT04461353
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Aerolized Hydroxychloroquine Sulfate, Placebo
Drug · Other
Lead sponsor
Pulmoquine Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects

NCT03346837
View directory record Official record
Conditions
Malignancies Multiple
Interventions
BMS-986205, Itraconazole, Rifampin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients

NCT03423186
View directory record Official record
Conditions
Sanfilippo Syndrome Type A (MPS IIIA)
Interventions
SOBI003
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
12 Months to 72 Months
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Oakland, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 23, 2026, 2:24 AM EDT